Skip to content

 POC Models for HBV Care

This survey, by the ICE-HBV POC working group, is part of an international collaborative research review project on HBV management in resource-limited settings (RLS). The main objective of the project is to improve access to/quality of HBV care in RLS and reduce HBV mortality and incidence.
1.Your age
2.Your gender
3.Where do you work (region)? Please select all apply and specify country/countries under Other.
4.Your professional role on HBV (elaborate on "other" field)
5.Increased HBV screening and diagnosis is important to achieve the WHO 2030 goal for HBV [Please rank in a 5-point scale: 1 being the highest priority, 5 being the lowest]
6.Increased access to antiviral therapy is important to achieve the WHO 2030 goal for HBV [Please rank in a 5-point scale: 1 being the highest priority, 5 being the lowest]
7.Increased rate of liver cancer surveillance is important to achieve the WHO 2030 goal for HBV [Please rank in a 5-point scale: 1 being the highest priority, 5 being the lowest]
8.Optimize strategies to prevent mother-to-child-transmission (MTCT) of HBV is important to achieve the WHO 2030 goal for HBV [Please rank in a 5-point scale: 1 being the highest priority, 5 being the lowest]
9.Optimize strategies to monitor HBV disease progression is important to achieve the WHO 2030 goal for HBV [Please rank in a 5-point scale: 1 being the highest priority, 5 being the lowest]
10.Please indicate which of the following tests/technology are available in your location (Check all that apply).
11.Should only WHO pre-qualified HBsAg rapid diagnostic tests be used for screening?
12.HBsAg positive rapid test result needs to be confirmed by standard HBsAg ELISA test before the participant undergoes further HBV evaluation?
13.Is anti-HDV screening routinely performed on HBsAg (+) patients in your location? 
14.If HBV DNA is in the treatment algorithm, an affordable POC HBV DNA test is necessary to deliver HBV care in my location
15.POC ALT, AST tests would be of value to deliver HBV care in my location
16.Are laboratories within reach to process dry blood spot (DBS) samples for HBV DNA (PCR assay) and other fibrosis, liver cancer biomarkers?
17.Transient Elastography (Fibroscan) is an important tool for liver fibrosis determination (1 being most important, 5 least important)
18.APR-1 (needs AST, platelet to calculate) is an important tool for liver fibrosis determination (1 being most important, 5 least important)
19.Fib-4 (needs age, AST, ALT platelet to calculate) is an important tool for liver fibrosis determination (1 being most important, 5 least important)
20.Validated novel fibrosis marker (collect DBS samples locally and perform assays in designated labs) is an important tool for liver fibrosis determination (1 being most important, 5 least important)
21.Which modality for fibrosis determination is available in your location? (Check none or all applied)
22.AFP is an important modality for liver cancer surveillance (1 being most important, 5 least important)
23.Abdominal ultrasound  is an important modality for liver cancer surveillance (1 being most important, 5 least important)
24.Abdominal ultrasound + AFP  is an important modality for liver cancer surveillance (1 being most important, 5 least important)
25.Abdominal CT scan  is an important modality for liver cancer surveillance (1 being most important, 5 least important)
26.Abdominal MRI  is an important modality for liver cancer surveillance (1 being most important, 5 least important)
27.Validated novel biomarkers (collect DBS locally and perform tests in designated laboratories) are important modalities for liver cancer surveillance (1 being most important, 5 least important)
28.Which liver cancer surveillance modality is being applied in your location (check none or all applied)
29.Please indicate which of the following HBV medication(s) are available in your location (check none or all applied)
30.How do you monitor medication compliance? (Check all applied)
31.At your location, are children (<18 years) with chronic hepatitis B offered antiviral therapy?
32.At your location, please indicate the approximate  makeup biological gender of the adult HBV populations being evaluated (must add up to 100% - do not include % symbol in answer)
33.In your location, please indicate the age composition of the adult HBV populations being evaluated (must add up to 100% - do not include % in answer)
34.Chronic hepatitis B patients with advanced hepatic fibrosis (stage 3 or 4) should have top priority in receiving antiviral therapy. [Can skip question if you are unsure]
35.Chronic hepatitis B patients with elevated ALT (regardless of HBV DNA Level) in the absence of other liver conditions (i.e. hepatitis C, fatty liver) should have priority in receiving antiviral therapy. [Can skip question if you are unsure]
36.Hepatitis B infected patients with HBeAg (+) and normal ALT should be routinely treated with antiviral therapy. [can skip question if you are unsure]
37.HBsAg(+) patients over 40 years of age should be routinely treated with antiviral therapy regardless of their HBV DNA, HBeAg and ALT status. [can skip question if you are unsure]
38.All HBsAg(+) adult patients should be routinely treated with antiviral therapy regardless of their HBV DNA, HBeAg and ALT status. [can skip question if you are unsure]
39.At your location, who can provide antiviral treatment for hepatitis B? (Check all that apply)
40.At your location, are adequate tiered training and resources available to the health providers for hepatitis B management?
41.At your location, can HBV counseling and evaluation be done in a stigma and discrimination free environment with confidentiality?
42.Should HBV diagnosis and treatment be integrated into the HIV care infrastructure if there is already one in place? 
43.Is universal screening of pregnant women for HBV at antenatal visit in place at your location?
44.What is the major barrier to screening pregnant women for HBV at your location?
45.Do you need support to ensure birth dose vaccination is universally provided?
46.In your location, what do the babies born to HBsAg mother receive to prevent MTCT of HBV?
47.At your location, are pregnant women with high level of viremia (HBV DNA >200,000 IU/ml) offered antiviral therapy during the third trimester to further prevent MTCT of HBV?
48.If the answer to Q47 is no, please provide reason (check all applied or comment)
49.If only HBeAg but not HBV DNA testing is available in your care setting, are you willing to use HBeAg positivity as a surrogate marker for high viremia and provide pregnant women with antiviral therapy to prevent MTCT of HBV? 
50.POC HBeAg test would be of value to deliver HBV care in my location
51.Do babies born to mothers with hepatitis B have routine HBsAg check at or after 7 months of age at your location? 
52.Do babies born to mother with hepatitis B have routine anti-HBs check at or after 7 months of age at your location? 
53.Country/ regional specific HBV management guidelines should be developed to achieve the 2030 WHO goal for HBV.